...
首页> 外文期刊>The Lancet >Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.
【24h】

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

机译:欧洲各地感染HIV-1的患者死亡率的变化模式。 EuroSIDA研究小组。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The introduction of combination antiretroviral therapy and protease inhibitors has led to reports of falling mortality rates among people infected with HIV-1. We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens. METHODS: We analysed data from EuroSIDA, which is a prospective, observational, European, multicentre cohort of 4270 HIV-1-infected patients. We compared death rates in each 6 month period from September, 1994, to March, 1998. FINDINGS: By March, 1998, 1215 patients had died. The mortality rate from March to September, 1995, was 23.3 deaths per 100 person-years of follow-up (95% CI 20.6-26.0), and fell to 4.1 per 100 person-years of follow-up (2.3-5.9) between September, 1997, and March, 1998. From March to September, 1997, the death rate was 65.4 per 100 person-years of follow-up for those on no treatment, 7.5 per 100 person-years of follow-up for patients on dual therapy, and 3.4 per 100 person-years of follow-up for patients on triple-combination therapy. Compared with patients who were followed up from September, 1994, to March, 1995, patients seen between September, 1997, and March, 1998, had a relative hazard of death of 0.16 (0.08-0.32), which rose to 0.90 (0.50-1.64) after adjustment for treatment. INTERPRETATION: Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level. A large proportion of the reduction in mortality could be explained by new treatments or combinations of treatments.
机译:背景:抗逆转录病毒疗法和蛋白酶抑制剂的联合使用已导致报道HIV-1感染者死亡率下降。我们检查了1994-98年间欧洲各地HIV-1感染患者的这些死亡率的变化,并评估了可以通过使用新的治疗方案来解释变化的程度。方法:我们分析了来自EuroSIDA的数据,该数据是对4270名HIV-1感染患者进行的前瞻性,观察性,欧洲多中心队列研究。我们比较了从1994年9月到1998年3月这6个月内的死亡率。结果:到1998年3月,已有1215例患者死亡。 1995年3月至9月的死亡率为每100人年随访23.3例死亡(95%CI 20.6-26.0),而在接下来的100年间,死亡率降至每100人年4.1例(2.3-5.9) 1997年9月和1998年3月。从1997年3月至9月,未接受治疗的患者的死亡率为每100人年65.4,而接受双重治疗的患者的死亡率为每100人年7.5。疗法,对于三联疗法的患者,每100人年3.4例随访。与1994年9月至1995年3月进行随访的患者相比,1997年9月至1998年3月之间看过的患者的相对死亡危险度为0.16(0.08-0.32),升至0.90(0.50- 1.64)调整后进行治疗。解释:自1995年9月以来,欧洲感染HIV-1的患者的死亡率一直在下降,到1998年初还不到以前水平的五分之一。死亡率降低的很大一部分可以通过新疗法或多种疗法来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号